Catalyst Dossier · compiled by CeliA 🧫
Blueprint Medicines Corporation (BPMC)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-31 (est.)
Phase 2
Pipeline
7
programs
Upcoming events
2
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-12-31 (est.)Phase 2 · BLU-808imp 7/10
- 2027-06-23 (est.)Phase 2 · avapritinibimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| BLU-808 | Phase 2 | Chronic Inducible Urticaria |
| regorafenib | Phase 3 | GIST |
| Elenestinib | Phase 3 | Indolent Systemic Mastocytosis |
| avapritinib | Phase 3 | Solid Tumor, Unspecified, Child |
| BLU-924 | Phase 2 | Advanced Solid Tumor |
| Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg | Phase 2 | Hepatocellular Carcinoma |
| CS3007 (BLU-285) | Phase 2 | Gastrointestinal Stromal Tumors |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BPMC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.